Normative Database elminda’s proprietary commercial database is based on the normative dataset that is the bedrock of our new 510(K) cleared BNA™ Platform V1.0 product.… Read More »Making the Complex Actionable: The Science and Process Behind the BNA™ Report
Background Identifying neurological biomarkers to aid with diagnoses, treatment effect evaluation of mood and cognitive symptoms, and treatment outcome prediction in major depressive disorder (MDD)… Read More »Identifying Neurological Biomarkers to Aid in Major Depressive Disorder (MDD) Diagnosis and Treatment
Introduction Mild cognitive impairment (MCI) defines the intermediate state between healthy cognition and early dementia1 and is not typical for normal brain aging2. In 2020… Read More »Screening & Managing MCI
BNA could improve the treatment of depression significantly by objectively measuring brain health, improving and saving lives. The BNATM Product provides brain mapping imaging technology supporting clinicians in diagnosing cognitive disorders and monitoring and quantifying improvement.
